Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.60 |
| ▸ | MAPT | P10636 | 7/20 | 0.60 |
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | HTT | P42858 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.58 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.58 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.58 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 6/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775594 | 0.87 | ALDH1A1 (0.66) | ALDH1A1MAPTNPC1SMN1; SMN2RAB9A | |
| SCHEMBL2636529 | 0.87 | ALDH1A1 (0.66) | ALDH1A1MAPTNPC1SMN1; SMN2RAB9A | |
| SCHEMBL3057301 | 0.84 | ALDH1A1 (0.46) | ALDH1A1MAPTNPC1SMN1; SMN2RAB9A | |
| SCHEMBL12092306 | 0.81 | HSD11B1 (0.62) | ALDH1A1MAPTNPC1SMN1; SMN2RAB9A | |
| SCHEMBL4134141 | 0.80 | MEN1 (0.44) | ALDH1A1MAPTNPC1SMN1; SMN2RAB9A | |
| SCHEMBL28269605 | 0.79 | ALDH1A1 (0.75) | ALDH1A1MAPTNPC1SMN1; SMN2RAB9A | |
| SCHEMBL3063864 | 0.79 | MAPT (0.65) | ALDH1A1MAPTSMN1; SMN2RAB9AHTT | |
| SCHEMBL31462930 | 0.75 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL3325905 | 0.75 | ALDH1A1 (0.61) | ALDH1A1MAPTNPC1SMN1; SMN2RAB9A | |
| SCHEMBL23859795 | 0.74 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2ALMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| US-5214042-A | Use of 5-phenyl-2-furan esters, amides and ketones as neuroprotective agents | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1993-05-25 | — | — | US | disclosed |
| US-5118708-A | USE OF 5-PHENYL-2-FURAN ESTERS, AMIDES AND KETONES AS NEUROPROTECTIVE AGENTS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1992-06-02 | — | — | US | disclosed |
| US-5023272-A | Use of 5-phenyl-2-furan esters and amides as antiepileptic agents | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1991-06-11 | — | — | US | disclosed |
| EP-0404231-A1 | The use of 5-phenyl-2 furan esters and amides as antiepileptic agents | Norwich Eaton Pharmaceuticals, Inc. (US) | 1990-12-27 | — | — | EP | disclosed |
| EP-0404233-A2 | Novel use of 5-phenyl-2-furan esters, amides and ketones as neuroprotective agents | Norwich Eaton Pharmaceuticals, Inc. (US) | 1990-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | ALDH1A1 2212/4885MAPT 1171/4885NPC1 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.